BELKYRA® is developed by Allergan.

What development phase is BELKYRA® in?

BELKYRA® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

BELKYRA®

Allergan · FDA-approved active Small molecule Quality 3/100

At a glance

Generic name	BELKYRA®
Sponsor	Allergan
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment (PHASE4)
Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour (PHASE4)
Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BELKYRA® CI brief — competitive landscape report
BELKYRA® updates RSS · CI watch RSS
Allergan portfolio CI